HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease

HBI-002 可预防镰状细胞病的血管闭塞危机

基本信息

  • 批准号:
    9789371
  • 负责人:
  • 金额:
    $ 70.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-07 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT The goal of the proposed project is to evaluate the potential of the gasotransmitter carbon monoxide (CO) as an agent to prevent Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease (SCD) using a novel oral formulation of CO (HBI-002). Numerous studies, both in vitro and in vivo, demonstrate that CO has cytoprotective properties through anti-oxidant, anti-inflammatory and anti-apoptotic processes. Our SBIR Phase 1 supported research has produced efficacy data similar to that reported in four studies using four different transgenic sickle cell mouse models that the heme oxygenase-1/CO pathway is key in SCD, demonstrating that low doses of CO are a novel approach to limiting vascular stasis and down-regulating inflammatory processes. These studies provide compelling support for a potential beneficial role for CO in limiting the morbidity of SCD. The safety and tolerability of CO has been demonstrated in eight successfully completed Phase 1 and Phase 2 studies, including two Phase 1b studies in SCD patients, using a variety of forms of CO administration. Moreover, there are ten ongoing clinical studies with CO, using various forms of CO administration. The absence of toxicity of CO at low levels of carboxy-hemoglobin (COHb) has been well defined in the literature, providing supportive safety data for the targeted COHb levels being considered for SCD patients with HBI-002. HBI-002, a liquid formulation of CO, is being developed for the prevention of VOCs in SCD. The administration of a defined dose of CO delivered by oral administration of HBI-002 enables the further development of CO as a therapeutic while obviating the problems associated with previously studied inhaled or intravenously administered carrier-metal CO, including environmental safety, dosing and compliance with chronic administration (inhaled CO) and carrier molecule toxicity, stability, and bioavailability (carrier-metal bound CO). Pharmacokinetic and pharmacodynamic studies in rodents with orally administered HBI-002 have demonstrated proof-of-concept feasibility, tolerability, and bioavailability. The next step in development is to evaluate the mechanistic, preclinical toxicologic, and clinical safety, tolerability, pharmacokinetic, and pharmacodynamic profile of HBI-002 for further development in sickle cell disease.
项目摘要/摘要 拟议项目的目标是评估气体变送器一氧化碳(CO)作为 一种使用新型口服制剂预防镰状细胞病(SCD)中血管闭塞危象(VOC)的药物 CO(HBI-002)。大量的体外和体内研究表明,CO具有细胞保护作用, 通过抗氧化、抗炎和抗细胞凋亡过程来发挥其特性。我们的SBIR第1阶段支持 一项研究得出的疗效数据与使用四种不同转基因镰刀的四项研究报告的数据相似 细胞小鼠模型,血红素加氧酶-1/CO途径是SCD的关键,表明低剂量的 CO是限制血管淤滞和下调炎症过程的新方法。这些 研究为CO在限制SCD发病率方面的潜在有益作用提供了令人信服的支持。 CO的安全性和耐受性已在8个成功完成的I期和II期研究中得到证实。 研究,包括在SCD患者中进行的两项Ib期研究,使用各种形式的CO给药。 此外,有10项正在进行的CO临床研究,使用各种形式的CO给药。的 在低水平的碳氧血红蛋白(COHb)下不存在CO毒性已经在文献中得到了很好的定义, 为患有HBI-002的SCD患者考虑的目标COHb水平提供支持性安全性数据。 HBI-002是一种CO液体制剂,正在开发用于预防SCD中的VOC。政府当局 通过口服HBI-002递送的确定剂量的CO的量使得CO进一步发展为 同时避免了与先前研究的吸入或静脉注射相关的问题, 管理载体金属CO,包括环境安全性,剂量和遵守慢性 在一些实施方案中,本发明的组合物可用于评价给药(吸入CO)和载体分子毒性、稳定性和生物利用度(载体-金属结合CO)。 啮齿类动物口服HBI-002的药代动力学和药效学研究表明, 证明了概念验证的可行性、耐受性和生物利用度。下一步的发展是 评价机制、临床前毒理学和临床安全性、耐受性、药代动力学和 HBI-002在镰状细胞病中的进一步开发的药效学特征。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN D BELCHER其他文献

JOHN D BELCHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN D BELCHER', 18)}}的其他基金

Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease
口服 N2O 疗法治疗镰状细胞病急性血管闭塞性疼痛
  • 批准号:
    10507724
  • 财政年份:
    2022
  • 资助金额:
    $ 70.24万
  • 项目类别:
Circulating Endothelial Cells and Microvesicles as Biomarkers for Gene Therapy in Sickle Cell Disease
循环内皮细胞和微泡作为镰状细胞病基因治疗的生物标志物
  • 批准号:
    10012207
  • 财政年份:
    2019
  • 资助金额:
    $ 70.24万
  • 项目类别:
Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
口服一氧化碳治疗可预防镰状细胞病的血管闭塞危机
  • 批准号:
    9257461
  • 财政年份:
    2016
  • 资助金额:
    $ 70.24万
  • 项目类别:
BIOLOGICAL MARKERS OF ALCOHOL CONSUMPTION
饮酒的生物标志物
  • 批准号:
    3111772
  • 财政年份:
    1989
  • 资助金额:
    $ 70.24万
  • 项目类别:
BIOLOGICAL MARKERS OF ALCOHOL CONSUMPTION
饮酒的生物标志物
  • 批准号:
    2044165
  • 财政年份:
    1989
  • 资助金额:
    $ 70.24万
  • 项目类别:
BIOLOGICAL MARKERS OF ALCOHOL CONSUMPTION
饮酒的生物标志物
  • 批准号:
    3111775
  • 财政年份:
    1989
  • 资助金额:
    $ 70.24万
  • 项目类别:

相似海外基金

Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
  • 批准号:
    23K07659
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
  • 批准号:
    23K15705
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
  • 批准号:
    23K19490
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
  • 批准号:
    10697567
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
  • 批准号:
    23K13905
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
  • 批准号:
    493138
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
  • 批准号:
    2223225
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
  • 批准号:
    10651054
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了